DUAL OREXIN RECEPTOR ANTAGONIST (DORA) SEBAGAI TERAPI INSOMNIA: SEBUAH TINJAUAN PUSTAKA

Dianda Faradiba Wardani; Oktafany Oktafany; Anisa Nuraisa Jausal; Oktadoni Saputra

doi:10.59003/nhj.v5i8.1832

Authors

Dianda Faradiba Wardani Universitas Lampung
Oktafany Oktafany Universitas Lampung
Anisa Nuraisa Jausal Universitas Lampung
Oktadoni Saputra Universitas Lampung

DOI:

https://doi.org/10.59003/nhj.v5i8.1832

Keywords:

Daridorexant, Insomnia, Lemborexant, Orexin, Suvorexant

Abstract

Insomnia affects more than 852 million adults worldwide and 43.7% of individuals aged ≥19 years in Indonesia, highlighting the need for effective and safe therapy. Benzodiazepines and Z-drugs are commonly used but are associated with risks of tolerance and dependence. Dual orexin receptor antagonists (DORAs) have emerged as a more selective therapeutic alternative. A systematic literature review was conducted using PubMed and Google Scholar, focusing on meta-analyses of suvorexant, lemborexant, and daridorexant. Suvorexant improved subjective total sleep time (MD −19.10), subjective time to sleep onset (MD −8.23), and subjective wake after sleep onset (MD −6.45). Lemborexant at doses of 5–10 mg was effective in improving wake after sleep onset (MD −19.90; −22.24) and sleep onset latency (MD −9.23; −12.56). Daridorexant at doses of 25–50 mg reduced wake after sleep onset (MD −0.30; −0.53) and latent persistent sleep (MD −0.30; −0.53). Adverse effects of DORAs include somnolence, daytime sleepiness, fatigue, abnormal dreams, and nasopharyngitis. Overall, DORAs demonstrated significant effectiveness on subjective sleep parameters compared with control groups, with variations in effect size and safety profiles. DORAs may be considered effective and safe treatments for insomnia, with drug and dose selection tailored to clinical needs.

Downloads

Download data is not yet available.

References

Alsaied, M.A., Elettreby, A.M., Serag, I., Rajput, J., Zabady, N.A., Li, H., et al. (2025). Efficacy and safety of lemborexant vs placebo in treating adults with insomnia disorder: a systematic review and meta-analysis of 1976 patients. Naunyn-Schmiedeberg’s archives of pharmacology. 398(10):12911–12926. DOI: 10.1007/s00210-025-04072-4

Barson, J.R. & Leibowitz, S.F. (2017). Orexin/Hypocretin System: Role in Food and Drug Overconsumption. International review of neurobiology. 136:199–237. DOI: 10.1016/bs.irn.2017.06.006

Benjafield, A. V, Sert, F.H., Malhotra, A., Martin, J.L., Morin, C.M., Maurer, L.F., et al. (2025). Estimation of the global prevalence and burden of insomnia : a systematic literature review-based analysis. 82(June). DOI: 10.1016/j.smrv.2025.102121

Berger, B., Dingemanse, J., Sabattini, G., Delahaye, S., Duthaler, U., Muehlan, C., et al. (2021). Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist. Clinical pharmacokinetics. 60(10):1349–1360. DOI: 10.1007/s40262-021-01028-8

Cada, D.J., Levien, T.L., & Baker, D.E. (2015). Suvorexant. Hospital pharmacy. 50(1):59–71. DOI: 10.1310/hpj5001-59

Dubey, A.K., Handu, S.S., & Mediratta, P.K. (2015). Suvorexant: The first orexin receptor antagonist to treat insomnia. Journal of pharmacology & pharmacotherapeutics. 6(2):118–121. DOI: 10.4103/0976-500X.155496

Edison, H. & Nainggolan, O. (2021). Hubungan Insomnia dengan Hipertensi. Buletin Penelitian Sistem Kesehatan. 24:46–56. DOI: 10.22435/hsr.v24i1.3579

Egmond, L.T. Van, Meth, E.M.S., Ilemosoglou, M., Annica, J., Benedict, C., & Engström, J. (2023). Effects of Acute Sleep Loss on Leptin , Ghrelin, and Adiponectin in Adults with Healthy Weight and Obesity : A Laboratory Study. The Obesity Society. (July 2022):635–641. DOI: 10.1002/oby.23616

Ferri, F.F. Ed. (2024). Ferri’s Clinical Advisor 2024. Philadelphia: Elsevier

Han, A.H., Burroughs, C.R., Falgoust, E.P., Hasoon, J., Hunt, G., Kakazu, J., et al. (2022). Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia. Health psychology research. 10(5):67898. DOI: 10.52965/001c.67898

Healy, W.J. & College, M. (2024). Insomnia : Advancements and Limitations of Current Management Strategies. 107–108

Hertenstein, E., Feige, B., Gmeiner, T., Kienzler, C., Spiegelhalder, K., Johann, A., et al. (2018). Insomnia as a predictor of mental disorders: A systematic review and meta-analysis. Sleep Medicine Reviews. DOI: 10.1016/j.smrv.2018.10.006

Id, E.A., Shaikh, A., Yasmin, F., Sughra, F., Sheikh, A., Owais, R., et al. (2023). Incidence of adverse cardiovascular events in patients with insomnia : A systematic review and meta-analysis of real-world data. (Dm):1–15. DOI: 10.1371/journal.pone.0291859

Irwin, M.R., Olmstead, R., & Carroll, J.E. (2017). Sleep Disturbance, Sleep Duration, and Inflammation: A Systematic Review and Meta-Analysis of Cohort Studies and Experimental Sleep Deprivation. Biol Psychiatry. 80(1):40–52. DOI: 10.1016/j.biopsych.2015.05.014.Sleep

Jiang, F., Li, H., Chen, Y., Lu, H., Ni, J., & Chen, G. (2023). Daridorexant for the treatment of insomnia disorder: A systematic review and meta-analysis of randomized controlled trials. Medicine. 102(7). Available: https://journals.lww.com/md-journal/fulltext/2023/02170/daridorexant_for_the_treatment_of_insomnia.27.aspx

Karna, B., Sankari, A., & Tatikonda, G. (2023). Sleep Disorder. Available: https://www.ncbi.nlm.nih.gov/books/NBK560720/ [2025, December 02]

Khara, N., Apte, A., Vyas, Y., Prajapati, D., Kshatriya, R., & Patel, S. (2024). The Intricacies of Insomnia: A Comprehensive Exploration. Korean Sleep Research Society. 21(2):65–72

Khazaie, H., Sadeghi, M., Khazaie, S., Hirshkowitz, M., & Sharafkhaneh, A. (2022). Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant. Frontiers in psychiatry. 13:1070522. DOI: 10.3389/fpsyt.2022.1070522

Kim, W., Kim, H., Kim, H., Kim, W., & Kim, H. (2024). Emerging and upcoming therapies in insomnia. 32(1):1–17

Kishi, T., Ikuta, T., Citrome, L., Sakuma, K., Hatano, M., Hamanaka, S., et al. (2025). Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Translational psychiatry. 15(1):211. DOI: 10.1038/s41398-025-03439-8

Lakbila-kamal, O., Foster-dingley, J.C., Albers, A., Jw, E., & Someren, V. (2024). Hyperarousal dynamics reveal an overnight increase boosted by insomnia ☆. Journal of Psychiatric Research. 179(September):279–285. DOI: 10.1016/j.jpsychires.2024.09.032

Lalovic, B., Majid, O., Aluri, J., Landry, I., Moline, M., & Hussein, Z. (2020). Population Pharmacokinetics and Exposure-Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder. Journal of clinical pharmacology. 60(12):1642–1654. DOI: 10.1002/jcph.1683

Landry, I., Nakai, K., Ferry, J., Aluri, J., Hall, N., Lalovic, B., et al. (2021). Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults. Clinical pharmacology in drug development. 10(2):153–165. DOI: 10.1002/cpdd.817

Levenson, J.C., Kay, D.B., & Buysse, D.J. (2015). The Pathophysiology of Insomnia. Chest. 147(4):1179–1192. DOI: 10.1378/chest.14-1617

Madari, S., Golebiowski, R., Mansukhani, M.P., & Kolla, B.P. (2021). Pharmacological Management of Insomnia. The American Society for Experimental NeuroTherapeutics. 44–52

Markham, A. (2022). Daridorexant: First Approval. Drugs. 82(5):601–607. DOI: 10.1007/s40265-022-01699-y

Mpharm, A.A. (2018). ‘Z’ -hypnotics versus benzodiazepines for the treatment of insomnia. Progress in Neurology and Psychiatry. 22(2)

Muehlan, C., Roch, C., & Dingemanse, J. (2023). The orexin story and orexin receptor antagonists for the treatment of insomnia. (February):1–16. DOI: 10.1111/jsr.13902

Naha, S., Ivaraman, M., & Sahota, P. (2024). Insomnia : A Current Review. Missouri Medicine. (February)

Pallanti, S. (2024). The role of benzodiazepines in common conditions : a narrative review focusing on lormetazepam. Wolters Kluwer Health. 139–147. DOI: 10.1097/YIC.0000000000000529

Ramar, K., Malhotra, R.K., Carden, K.A., Martin, J.L., Abbasi-feinberg, F., & Aurora, R.N. (2021). Sleep is essential to health : an American Academy of Sleep Medicine position statement

Reus, V.I. & Lindqvist, D. Eds. (2019). Psychopharmacology of Neurologic Disease. Amsterdam: Elsevier

Rhyne, D.N. & Anderson, S.L. (2015). Suvorexant in insomnia: efficacy, safety and place in therapy. Therapeutic advances in drug safety. 6(5):189–195. DOI: 10.1177/2042098615595359

Rocha, R.B., Bomtempo, F.F., Cenci, G.I., Paulo, J., & Telles, M. (2023). Dual orexin receptor antagonists for the treatment of insomnia : systematic review and network meta-analysis Antagonistas duais do receptor de orexina para o tratamento da insônia : revisão sistemática e metanálise em rede. 109(2)

Sarathi Chakraborty, D., Choudhury, S., & Lahiry, S. (2023). Daridorexant, a Recently Approved Dual Orexin Receptor Antagonists (DORA) in Treatment of Insomnia. Sleep science (Sao Paulo, Brazil). 16(2):256–264. DOI: 10.1055/s-0043-1770805

Sateia, M.J., Buysse, D.J., Krystal, A.D., Neubauer, D.N., & Heald, J.L. (2017). Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults : An American Academy of Sleep Medicine Clinical Practice Guideline. 13(2):307–349. DOI: https://doi.org/10.5664/jcsm.6470

Schwartz, M.D. & Kilduff, T.S. (2016). The Neurobiology of Sleep and Wakefulness. HHS Public Accesd. 38(4):615–644. DOI: 10.1016/j.psc.2015.07.002.THE

Taylor, D.M., Barnes, T.R.E., & Young, A.H. (2021). The Maudsley Prescribing Guidelines in Psychiatry. 14th ed. Chichester,: John Wiley & Son

Vasudeva, S., Wong, S., Le, G.H., Dri, C.E., Teopiz, K.M., Ho, R., et al. (2025). Efficacy and safety profiles of FDA-approved dual orexin receptor antagonists in depression: A systematic review of pre-clinical and clinical studies. Journal of Psychiatric Research. 191:752–769. DOI: https://doi.org/10.1016/j.jpsychires.2025.10.001

Yun, S. & Jo, S. (2021). Understanding insomnia as systemic disease. Yeungnam University College of Medicine. 38(4):267–274